CompletedNot applicableNCT01442064

An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Genentech, Inc.
Principal Investigator
Phillip Lai, M.D., MD
Genentech, Inc.
Intervention
Ranibizumab 0.5 mg(drug)
Enrollment
608 enrolled
Eligibility
18 years · All sexes
Timeline
20082010

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01442064 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials